X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline and JT-09.
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2020
Details:
Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Sixmo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Accord healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
